Bio-Rad Introduces Pioneer Antibody Discovery Platform for Therapeutic Development

In November 2022, Bio-Rad Laboratories launched its Pioneer Antibody Discovery Platform, a new antibody discovery service specifically designed to develop best-in-class biologic candidates.

According to a Nov. 14, 2022 company press release, the Pioneer platform has an enhanced phage display library that includes more than 200 billion unique sequences. Additionally, the platform is capable of identifying high-affinity antibody candidates via Bio-Rad’s SpyDisplay selection technology. The technology is optimized for candidates suitable for drug development.

The platform is tailored to specific client requirements and uses proprietary TrailBlazer technology to provide prototypes of therapeutic antibodies in various formats for streamlined lead identification. Final immunoglobulin g antibodies are delivered functionally characterized with a complete data package and sequences. Customers retain exclusivity and ownership over antibody sequences produced from the platform.

"The commercial launch of Pioneer Platform demonstrates Bio-Rad's focus on supporting the biotherapeutic space," said John Cardone, marketing manager, Custom Antibodies, Life Science Group, Bio-Rad, in the release. "With decades of experience in antibody discovery, our team of scientists and technical specialists accelerate and simplify the process to identify functional biologics for the targets of interest."

Source: Bio-Rad Laboratories